MANGOCEUTICALS, INC. (MGRX): M&A transaction — Mangoceuticals acquires mushroom patent for 515k shares; CEO Cohen secures 75.5% voting control of subsidiary M&P

MANGOCEUTICALS, INC.

Acquired mushroom patent WO 2023/086647 from Greenfield Investments for 515,000 restricted shares of common stock.
Contributed substantially all assets (MangoRx Mexico and UK) to new subsidiary Mango & Peaches Corp.
CEO Jacob Cohen received 1.7M common shares (25.4%) and Series A preferred with 51% voting power, totaling 75.5% voting control of M&P.
CEO base salary raised to $360k/year; severance increased to 3x salary plus target bonus; term extended to Dec 2027.
Granted Greenfield a co-exclusive license to patents for 10% royalty on gross sales starting Dec 2025.

item 1.01 item 5.02 item 2.01 item 3.02 item 3.03 item 5.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

MANGOCEUTICALS, INC. completed an acquisition involving Greenfield Investments, Ltd for 515,000 shares of the Company’s restricted common stock (closed 2024-12-13).

Action: acquisition
Counterparty: Greenfield Investments, Ltd
Consideration: 515,000 shares of the Company’s restricted common stock
Closing: 2024-12-13

Exact text from the filing

certain patents owned by Greenfield, related to nutraceutical compositions using fungal compounds derived from mushrooms (collectively, the “ Patents ”), in consideration for 515,000 shares of the Company’s restricted common stock (the “ IP Purchase Shares ”). The IP Purchase Agreement, and the purchase of the Patents, closed on December 13, 2024, upon the

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-050830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.